Physician Photo

Scott R. Plotkin, MD

Director, Neurofibromatosis Clinic

Director, MGH/DFCI/BWH Neuro-Oncology Fellowship Program

  • Phone: 617-724-8770
Departments
Department of Neurology

Specialties

  • Cancer Center
  • Neuro-Oncology (Brain)
  • Neurofibromatosis
  • MassGeneral Hospital for Children
  • Neurology
Clinical Interests
Neurofibromatosis
Primary brain tumors
Brain and spinal cord tumors
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, PhD, Tulane University School of Medicine
Residency, Brigham and Women's Hospital
Fellowship, Massachusetts General Hospital
Board Certifications
Neurology, American Board of Psychiatry and Neurology
Gender
Male
Patient Gateway
Yes, learn more
Patient Age Group
Adult and pediatric
Accepting New Patients
Yes

Publications

McQueen M, MacCollin M, Gusella J, Plotkin SR. Patient and Physician Attitudes Toward Clinical Trials in Neurofibromatosis 1. J Neurosci Nurs. 2008;40(6):341-345.

Cai W, Kassarjian A, Bredella M, Yochido H, Harris G, Mautner V, Wenzel R, and Plotkin SR. Determination of Tumor Burden in NF1, NR2, and Schwannomatosis on Whole Body MR Images. Radiology. 2009; (250): 665-673.

Plotkin SR, Halpin C, Blakeley JO, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J. Neuroonc. 2009;93(1):61-77.

Plotkin SR, Stemmer-Rachamimov AO, Barker II FG Halpin C, Padera TP, Tyrell A, Sorensen AG, Jain RK and di Tomaso E. Hearing improvement after bevacizumab in patient with neurofibromatosis 2. NEJM. 2009;361(4): 358-367.

El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE. Use of Video to FAcilitate End-of-Life Discussions with Patients With Cancer: A Randomized Controlled Trial. J Clin Oncol 2009.

Treatment reverses hearing loss in patients with neurofibromatosis type 2

Neurofibromatosis type 2 (NF2) is a genetic condition associated with bilateral vestibular schwannomas. It is rare, affecting only about one in 25,000 people.

Antiangiogenesis treatment improves hearing in some NF2 patients

Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). The study by researchers from Massachusetts General Hospital (MGH) represents the first report of a successful NF2 treatment not involving surgery or radiation.

Pappas Center for Neuro Oncology
55 Fruit Street
Boston, MA 02114

Phone: 617-724-8770
Fax: 617-724-8769